tiprankstipranks
Voyager Therapeutics (DE:VT6)
FRANKFURT:VT6
Germany Market
VT6
Voyager Therapeutics
RESEARCH TOOLSreports

Voyager Therapeutics (VT6) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

VT6 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Voyager
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VT6 Stock 12 Month Forecast

Average Price Target

€14.74
▲(464.59% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is €14.74 with a high forecast of €21.67 and a low forecast of €6.93. The average price target represents a 464.59% change from the last price of €2.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","22":"€22","6.25":"€6.25","11.5":"€11.5","16.75":"€16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.6701065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.73567242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€14.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.93443408,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.25,11.5,16.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.912,4.354931269230769,5.797862538461539,7.240793807692308,8.683725076923077,10.126656346153846,11.569587615384616,13.012518884615385,14.455450153846154,15.898381423076923,17.341312692307692,18.78424396153846,20.22717523076923,{"y":21.6701065,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.912,3.8215132630769233,4.731026526153846,5.640539789230769,6.5500530523076925,7.459566315384616,8.369079578461537,9.278592841538462,10.188106104615386,11.097619367692307,12.007132630769231,12.916645893846155,13.826159156923076,{"y":14.73567242,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.912,3.221418006153846,3.5308360123076925,3.8402540184615384,4.149672024615384,4.4590900307692305,4.768508036923077,5.077926043076923,5.387344049230769,5.696762055384616,6.006180061538462,6.315598067692308,6.6250160738461545,{"y":6.93443408,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.398,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.512,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.758,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.754,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.328,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.264,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.084,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.198,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.174,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.912,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€21.67Average Price Target€14.74Lowest Price Target€6.93
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:VT6
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€21.67
Buy
730.27%
Upside
Reiterated
07/20/26
Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones
Canaccord Genuity Analyst forecast on DE:VT6
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€10.4
Buy
298.53%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Axsome Therapeutics (NASDAQ: AXSM) and Nurix Therapeutics (NASDAQ: NRIX)
Wedbush Analyst forecast on DE:VT6
Yun Zhong
Wedbush
Wedbush
€6.93
Buy
165.69%
Upside
Reiterated
07/14/26
Analysts' Top Healthcare Picks: HCA Healthcare (HCA), Voyager Therapeutics (VYGR)
TD Cowen Analyst forecast on DE:VT6
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Phathom Pharmaceuticals (NASDAQ: PHAT) and Voyager Therapeutics (NASDAQ: VYGR)
Guggenheim Analyst forecast on DE:VT6
Debjit Chattopadhyay
Guggenheim
Guggenheim
€19.07
Buy
630.64%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)
Oppenheimer Analyst forecast on DE:VT6
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€15.6
Buy
497.80%
Upside
Reiterated
05/08/26
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Citi Analyst forecast on DE:VT6
Samantha Semenkow
Citi
Citi
€9.53
Buy
265.32%
Upside
Reiterated
03/23/26
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
Truist Financial Analyst forecast on DE:VT6
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), Voyager Therapeutics (NASDAQ: VYGR) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Wells Fargo Analyst forecast on DE:VT6
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€8.67
Buy
232.11%
Upside
Reiterated
03/11/26
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Leerink Partners Analyst forecast on DE:VT6
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
€9.53
Buy
265.32%
Upside
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Voyager Therapeutics (NASDAQ: VYGR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:VT6
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€21.67
Buy
730.27%
Upside
Reiterated
07/20/26
Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones
Canaccord Genuity Analyst forecast on DE:VT6
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€10.4
Buy
298.53%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Axsome Therapeutics (NASDAQ: AXSM) and Nurix Therapeutics (NASDAQ: NRIX)
Wedbush Analyst forecast on DE:VT6
Yun Zhong
Wedbush
Wedbush
€6.93
Buy
165.69%
Upside
Reiterated
07/14/26
Analysts' Top Healthcare Picks: HCA Healthcare (HCA), Voyager Therapeutics (VYGR)
TD Cowen Analyst forecast on DE:VT6
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Phathom Pharmaceuticals (NASDAQ: PHAT) and Voyager Therapeutics (NASDAQ: VYGR)
Guggenheim Analyst forecast on DE:VT6
Debjit Chattopadhyay
Guggenheim
Guggenheim
€19.07
Buy
630.64%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)
Oppenheimer Analyst forecast on DE:VT6
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€15.6
Buy
497.80%
Upside
Reiterated
05/08/26
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Citi Analyst forecast on DE:VT6
Samantha Semenkow
Citi
Citi
€9.53
Buy
265.32%
Upside
Reiterated
03/23/26
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
Truist Financial Analyst forecast on DE:VT6
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), Voyager Therapeutics (NASDAQ: VYGR) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Wells Fargo Analyst forecast on DE:VT6
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€8.67
Buy
232.11%
Upside
Reiterated
03/11/26
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Leerink Partners Analyst forecast on DE:VT6
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
€9.53
Buy
265.32%
Upside
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Voyager Therapeutics (NASDAQ: VYGR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Voyager Therapeutics

3 Months
Debjit ChattopadhyayGuggenheim
Success Rate
7/19 ratings generated profit
37%
Average Return
-0.21%
reiterated a buy rating 2 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of -0.21% per trade.
1 Year
Sumant KulkarniCanaccord Genuity
Success Rate
10/31 ratings generated profit
32%
Average Return
-17.75%
reiterated a buy rating 22 days ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 32.26% of your transactions generating a profit, with an average return of -17.75% per trade.
2 Years
Sumant KulkarniCanaccord Genuity
Success Rate
2/31 ratings generated profit
6%
Average Return
-26.11%
reiterated a buy rating 22 days ago
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 6.45% of your transactions generating a profit, with an average return of -26.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VT6 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
10
10
15
10
13
Buy
2
2
3
2
3
Hold
26
35
50
41
31
Sell
1
4
7
7
5
Strong Sell
0
0
0
0
0
total
39
51
75
60
52
In the current month, VT6 has received 16 Buy Ratings, 31 Hold Ratings, and 5 Sell Ratings. VT6 average Analyst price target in the past 3 months is 14.74.
Each month's total comprises the sum of three months' worth of ratings.

VT6 Financial Forecast

VT6 Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

VT6 Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

VT6 Stock Forecast FAQ

What is DE:VT6’s average 12-month price target, according to analysts?
Based on analyst ratings, Voyager Therapeutics’s 12-month average price target is 14.74.
    What is DE:VT6’s upside potential, based on the analysts’ average price target?
    Voyager Therapeutics has 464.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Voyager Therapeutics a Buy, Sell or Hold?
          Voyager Therapeutics has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Voyager Therapeutics’s share price target?
            The average share price target for Voyager Therapeutics is 14.74. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €21.67 ,and the lowest forecast is €6.93. The average share price target represents 464.59% Increase from the current price of €2.61.
              What do analysts say about Voyager Therapeutics?
              Voyager Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Voyager Therapeutics?
                To buy shares of DE:VT6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.